Last reviewed · How we verify

Reduced doses of anti-TNF

Spanish Clinical Pharmacology Society · FDA-approved active Small molecule

Reduced doses of anti-TNF is a TNF inhibitor Small molecule drug developed by Spanish Clinical Pharmacology Society. It is currently FDA-approved for Rheumatoid arthritis (maintenance therapy at reduced dose), Inflammatory bowel disease (Crohn's disease and ulcerative colitis), Ankylosing spondylitis. Also known as: Adalimumab: 40 mg / 3 weeks, Etanercept: 50 mg / 10 days, Golimumab: 50 mg / 6 weeks, Infliximab: 3 mg/kg / 8 weeks.

Reduced doses of anti-TNF agents lower the concentration of tumor necrosis factor inhibitors to minimize immunosuppression while maintaining therapeutic benefit.

Reduced doses of anti-TNF agents lower the concentration of tumor necrosis factor inhibitors to minimize immunosuppression while maintaining therapeutic benefit. Used for Rheumatoid arthritis (maintenance therapy at reduced dose), Inflammatory bowel disease (Crohn's disease and ulcerative colitis), Ankylosing spondylitis.

At a glance

Generic nameReduced doses of anti-TNF
Also known asAdalimumab: 40 mg / 3 weeks, Etanercept: 50 mg / 10 days, Golimumab: 50 mg / 6 weeks, Infliximab: 3 mg/kg / 8 weeks
SponsorSpanish Clinical Pharmacology Society
Drug classTNF inhibitor
TargetTNF-α (Tumor Necrosis Factor-alpha)
ModalitySmall molecule
Therapeutic areaImmunology
PhaseFDA-approved

Mechanism of action

Anti-TNF drugs (such as infliximab, adalimumab, or etanercept) block tumor necrosis factor-alpha, a key inflammatory cytokine. By using reduced doses, this therapeutic approach aims to balance efficacy in controlling inflammatory diseases with decreased risk of serious infections and other adverse effects associated with TNF inhibition. This strategy is particularly relevant for patients who have achieved disease control and may tolerate lower maintenance doses.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Reduced doses of anti-TNF

What is Reduced doses of anti-TNF?

Reduced doses of anti-TNF is a TNF inhibitor drug developed by Spanish Clinical Pharmacology Society, indicated for Rheumatoid arthritis (maintenance therapy at reduced dose), Inflammatory bowel disease (Crohn's disease and ulcerative colitis), Ankylosing spondylitis.

How does Reduced doses of anti-TNF work?

Reduced doses of anti-TNF agents lower the concentration of tumor necrosis factor inhibitors to minimize immunosuppression while maintaining therapeutic benefit.

What is Reduced doses of anti-TNF used for?

Reduced doses of anti-TNF is indicated for Rheumatoid arthritis (maintenance therapy at reduced dose), Inflammatory bowel disease (Crohn's disease and ulcerative colitis), Ankylosing spondylitis, Psoriatic arthritis.

Who makes Reduced doses of anti-TNF?

Reduced doses of anti-TNF is developed and marketed by Spanish Clinical Pharmacology Society (see full Spanish Clinical Pharmacology Society pipeline at /company/spanish-clinical-pharmacology-society).

Is Reduced doses of anti-TNF also known as anything else?

Reduced doses of anti-TNF is also known as Adalimumab: 40 mg / 3 weeks, Etanercept: 50 mg / 10 days, Golimumab: 50 mg / 6 weeks, Infliximab: 3 mg/kg / 8 weeks.

What drug class is Reduced doses of anti-TNF in?

Reduced doses of anti-TNF belongs to the TNF inhibitor class. See all TNF inhibitor drugs at /class/tnf-inhibitor.

What development phase is Reduced doses of anti-TNF in?

Reduced doses of anti-TNF is FDA-approved (marketed).

What are the side effects of Reduced doses of anti-TNF?

Common side effects of Reduced doses of anti-TNF include Infections (including serious infections), Tuberculosis reactivation, Injection site reactions, Headache, Upper respiratory tract infections.

What does Reduced doses of anti-TNF target?

Reduced doses of anti-TNF targets TNF-α (Tumor Necrosis Factor-alpha) and is a TNF inhibitor.

Related